IMP3 expression in small-intestine neuroendocrine neoplasms

a new predictor of recurrence

Sara Massironi, Alessandro Del Gobbo, Federica Cavalcoli, Stefano Fiori, Dario Conte, Alessio Pellegrinelli, Massimo Milione, Stefano Ferrero

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Small-intestine neuroendocrine neoplasms are heterogeneous neoplasms arising from endocrine cells of the intestinal mucosa. Ki-67 is the main determinant of prognosis in neuroendocrine neoplasms. However, the search for new prognostic makers represents a key point with regard to small-intestine neuroendocrine neoplasms. The oncofetal protein IMP3 plays a role in cell growth and its expression has a prognostic value in lung neoplasms. Methods: From January 1998 to August 2015, all the consecutive small-intestine neuroendocrine neoplasms patients suitable for surgery were included: 51 patients (32 males, median age 68 years) had small-intestine neuroendocrine neoplasms classified according to the WHO 2010 classification. In all the cases IMP3 expression was evaluated on primary tumors and, when available, on nodal and distant metastases. The medical records and pathological slides of these patients were used to determine the clinical characteristics, pathological diagnoses, and outcome information. Results: The overall 5-year and 10-year survival rate were 53.9 and 42% respectively. At Cox proportional hazards regression grading was the major factor influencing both OS and progression-free survival at univariate (p = 0.0002 and 0.0051, respectively) and multivariate analysis (p = 0.0004 and 0.0043, respectively). Also IMP3 expression at the nodal metastases resulted a factor significantly associated with progression-free survival at both univariate (p = 0.0066) and multivariate analysis (p = 0.0059, HR 3.58). IMP3 expression did not correlate with the Ki-67 (p = n.s.). Conclusions: In this study, IMP3 at the nodal site resulted to be associated with low progression-free survival in small-intestine neuroendocrine neoplasms, independently of the Ki-67 index. We suggest that the integration of IMP3 and Ki-67 would help better stratify the risk of progression in small-intestine neuroendocrine neoplasms.

Original languageEnglish
Pages (from-to)360-367
Number of pages8
JournalEndocrine
Volume58
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

Intestinal Neoplasms
Small Intestine
Recurrence
Disease-Free Survival
Multivariate Analysis
Neoplasm Metastasis
Neoplasms
Endocrine Cells
Intestinal Mucosa
Medical Records
Lung Neoplasms
Survival Rate
Growth

Keywords

  • IMP3 expression
  • Nodal metastasis
  • Prognostic makers
  • Small-intestine neuroendocrine neoplasms

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

IMP3 expression in small-intestine neuroendocrine neoplasms : a new predictor of recurrence. / Massironi, Sara; Del Gobbo, Alessandro; Cavalcoli, Federica; Fiori, Stefano; Conte, Dario; Pellegrinelli, Alessio; Milione, Massimo; Ferrero, Stefano.

In: Endocrine, Vol. 58, No. 2, 2017, p. 360-367.

Research output: Contribution to journalArticle

Massironi, Sara ; Del Gobbo, Alessandro ; Cavalcoli, Federica ; Fiori, Stefano ; Conte, Dario ; Pellegrinelli, Alessio ; Milione, Massimo ; Ferrero, Stefano. / IMP3 expression in small-intestine neuroendocrine neoplasms : a new predictor of recurrence. In: Endocrine. 2017 ; Vol. 58, No. 2. pp. 360-367.
@article{9925ecbf452b40c88e8abd11f021991f,
title = "IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence",
abstract = "Purpose: Small-intestine neuroendocrine neoplasms are heterogeneous neoplasms arising from endocrine cells of the intestinal mucosa. Ki-67 is the main determinant of prognosis in neuroendocrine neoplasms. However, the search for new prognostic makers represents a key point with regard to small-intestine neuroendocrine neoplasms. The oncofetal protein IMP3 plays a role in cell growth and its expression has a prognostic value in lung neoplasms. Methods: From January 1998 to August 2015, all the consecutive small-intestine neuroendocrine neoplasms patients suitable for surgery were included: 51 patients (32 males, median age 68 years) had small-intestine neuroendocrine neoplasms classified according to the WHO 2010 classification. In all the cases IMP3 expression was evaluated on primary tumors and, when available, on nodal and distant metastases. The medical records and pathological slides of these patients were used to determine the clinical characteristics, pathological diagnoses, and outcome information. Results: The overall 5-year and 10-year survival rate were 53.9 and 42{\%} respectively. At Cox proportional hazards regression grading was the major factor influencing both OS and progression-free survival at univariate (p = 0.0002 and 0.0051, respectively) and multivariate analysis (p = 0.0004 and 0.0043, respectively). Also IMP3 expression at the nodal metastases resulted a factor significantly associated with progression-free survival at both univariate (p = 0.0066) and multivariate analysis (p = 0.0059, HR 3.58). IMP3 expression did not correlate with the Ki-67 (p = n.s.). Conclusions: In this study, IMP3 at the nodal site resulted to be associated with low progression-free survival in small-intestine neuroendocrine neoplasms, independently of the Ki-67 index. We suggest that the integration of IMP3 and Ki-67 would help better stratify the risk of progression in small-intestine neuroendocrine neoplasms.",
keywords = "IMP3 expression, Nodal metastasis, Prognostic makers, Small-intestine neuroendocrine neoplasms",
author = "Sara Massironi and {Del Gobbo}, Alessandro and Federica Cavalcoli and Stefano Fiori and Dario Conte and Alessio Pellegrinelli and Massimo Milione and Stefano Ferrero",
year = "2017",
doi = "10.1007/s12020-017-1249-x",
language = "English",
volume = "58",
pages = "360--367",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press Inc.",
number = "2",

}

TY - JOUR

T1 - IMP3 expression in small-intestine neuroendocrine neoplasms

T2 - a new predictor of recurrence

AU - Massironi, Sara

AU - Del Gobbo, Alessandro

AU - Cavalcoli, Federica

AU - Fiori, Stefano

AU - Conte, Dario

AU - Pellegrinelli, Alessio

AU - Milione, Massimo

AU - Ferrero, Stefano

PY - 2017

Y1 - 2017

N2 - Purpose: Small-intestine neuroendocrine neoplasms are heterogeneous neoplasms arising from endocrine cells of the intestinal mucosa. Ki-67 is the main determinant of prognosis in neuroendocrine neoplasms. However, the search for new prognostic makers represents a key point with regard to small-intestine neuroendocrine neoplasms. The oncofetal protein IMP3 plays a role in cell growth and its expression has a prognostic value in lung neoplasms. Methods: From January 1998 to August 2015, all the consecutive small-intestine neuroendocrine neoplasms patients suitable for surgery were included: 51 patients (32 males, median age 68 years) had small-intestine neuroendocrine neoplasms classified according to the WHO 2010 classification. In all the cases IMP3 expression was evaluated on primary tumors and, when available, on nodal and distant metastases. The medical records and pathological slides of these patients were used to determine the clinical characteristics, pathological diagnoses, and outcome information. Results: The overall 5-year and 10-year survival rate were 53.9 and 42% respectively. At Cox proportional hazards regression grading was the major factor influencing both OS and progression-free survival at univariate (p = 0.0002 and 0.0051, respectively) and multivariate analysis (p = 0.0004 and 0.0043, respectively). Also IMP3 expression at the nodal metastases resulted a factor significantly associated with progression-free survival at both univariate (p = 0.0066) and multivariate analysis (p = 0.0059, HR 3.58). IMP3 expression did not correlate with the Ki-67 (p = n.s.). Conclusions: In this study, IMP3 at the nodal site resulted to be associated with low progression-free survival in small-intestine neuroendocrine neoplasms, independently of the Ki-67 index. We suggest that the integration of IMP3 and Ki-67 would help better stratify the risk of progression in small-intestine neuroendocrine neoplasms.

AB - Purpose: Small-intestine neuroendocrine neoplasms are heterogeneous neoplasms arising from endocrine cells of the intestinal mucosa. Ki-67 is the main determinant of prognosis in neuroendocrine neoplasms. However, the search for new prognostic makers represents a key point with regard to small-intestine neuroendocrine neoplasms. The oncofetal protein IMP3 plays a role in cell growth and its expression has a prognostic value in lung neoplasms. Methods: From January 1998 to August 2015, all the consecutive small-intestine neuroendocrine neoplasms patients suitable for surgery were included: 51 patients (32 males, median age 68 years) had small-intestine neuroendocrine neoplasms classified according to the WHO 2010 classification. In all the cases IMP3 expression was evaluated on primary tumors and, when available, on nodal and distant metastases. The medical records and pathological slides of these patients were used to determine the clinical characteristics, pathological diagnoses, and outcome information. Results: The overall 5-year and 10-year survival rate were 53.9 and 42% respectively. At Cox proportional hazards regression grading was the major factor influencing both OS and progression-free survival at univariate (p = 0.0002 and 0.0051, respectively) and multivariate analysis (p = 0.0004 and 0.0043, respectively). Also IMP3 expression at the nodal metastases resulted a factor significantly associated with progression-free survival at both univariate (p = 0.0066) and multivariate analysis (p = 0.0059, HR 3.58). IMP3 expression did not correlate with the Ki-67 (p = n.s.). Conclusions: In this study, IMP3 at the nodal site resulted to be associated with low progression-free survival in small-intestine neuroendocrine neoplasms, independently of the Ki-67 index. We suggest that the integration of IMP3 and Ki-67 would help better stratify the risk of progression in small-intestine neuroendocrine neoplasms.

KW - IMP3 expression

KW - Nodal metastasis

KW - Prognostic makers

KW - Small-intestine neuroendocrine neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85013102496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013102496&partnerID=8YFLogxK

U2 - 10.1007/s12020-017-1249-x

DO - 10.1007/s12020-017-1249-x

M3 - Article

VL - 58

SP - 360

EP - 367

JO - Endocrine

JF - Endocrine

SN - 1355-008X

IS - 2

ER -